NEI to test Lucentis and Avastin for treating eye disorder

10/2/2006 | Bloomberg

The National Eye Institute may test Genentech's eye drug Lucentis and its cancer drug Avastin to compare the two in treating age-related macular degeneration. However, the institute said some major funding issues remain in creating the trial.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY